EMAIL THIS PAGE TO A FRIEND

Acta biomaterialia

Therapeutic efficacy of doxorubicin delivery by a CO2 generating liposomal platform in breast carcinoma.


PMID 26102337

Abstract

Drug delivery using thermosensitive liposomes (TSL) has significant potential for tumor drug targeting and can be combined with local hyperthermia to trigger drug release. Although TSL-mediated drug delivery can be effective by itself, we developed doxorubicin (DOX)-containing CO2 bubble-generating TSL (TSL-C) that were found to enhance the antitumor effects of DOX owing to the synergism between burst release of drug and hyperthermia-induced CO2 generation. An ultrasound imaging system was used to monitor hyperthermia-induced CO2 generation in TSL-C and the results revealed that hyperthermia-induced CO2 generation in TSL-C led to increased DOX release compared to that observed for non-CO2-generating TSL. Moreover, TSL-C significantly inhibited the tumor growth in MDA-MB-231 tumor-bearing mice compared to TSL (p<0.004). Taken together, we demonstrated that the TSL-C platform increased the therapeutic efficacy of cancer chemotherapy and showed the applicability of this approach to increase drug release within the tumor microenvironment. As a novel and highly effective drug delivery platform, TSL-C has great potential for use in a broad range of applications for the treatment of various human diseases. We have developed a novel method for drug release from liposomes by gas (CO2) generation in tumor microenvironment. In addition, we demonstrate therapeutic efficacy in breast carcinoma. CO2-generated liposomal doxorubicin is a novel and highly attractive delivery system for anticancer drug with the potential for broad applications in human disease.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

220116
2-Hydroxybutyric acid sodium salt, 97%
C4H7NaO3
RES1427A-A7
Ammonium sulfate, PharmaGrade, NF, Manufactured under appropriate GMP controls for pharma or biopharmaceutical production.
H8N2O4S
A4418
Ammonium sulfate, for molecular biology, ≥99.0%
H8N2O4S
A6387
Ammonium sulfate, ReagentPlus®, ≥99.0%
H8N2O4S
A3920
Ammonium sulfate, plant cell culture tested, ≥99.0%
H8N2O4S
09978
Ammonium sulfate, BioUltra, ≥99.5% (T)
H8N2O4S
A2939
Ammonium sulfate, BioXtra, ≥99.0%
H8N2O4S
204501
Ammonium sulfate, 99.999% trace metals basis
H8N2O4S
451975
Ammonium sulfate-14N2 solution, 99.99 atom % 14N, 40 wt. % in H2O
H814N2O4S
485411
Ammonium-14N2 sulfate, 99.99 atom % 14N
H814N2O4S
485306
Ammonium-14N2 sulfate solution, 40 wt. % in H2O, 99.99 atom % 14N
H814N2O4S
608602
Ammonium-14N2,sulfate-16O4, 99.99 atom % 14N, 99.99 atom % 16O
H814N216O4S
791725
Citric acid, anhydrous, free-flowing, Redi-Dri, ACS reagent, ≥99.5%
C6H8O7
C2404
Citric acid, anhydrous, cell culture tested, plant cell culture tested
C6H8O7
251275
Citric acid, ACS reagent, ≥99.5%
C6H8O7
C83155
Citric acid, 99%
C6H8O7
C0759
Citric acid, 99%
C6H8O7
27487
Citric acid, BioUltra, anhydrous, ≥99.5% (T)
C6H8O7
W230618
Citric acid, ≥99.5%, FCC, FG
C6H8O7
D1515
Doxorubicin hydrochloride, 98.0-102.0% (HPLC)
C27H29NO11 · HCl
44583
Doxorubicin hydrochloride, suitable for fluorescence, 98.0-102.0% (HPLC)
C27H29NO11 · HCl